CALL US TOLL FREE 844-248-3717



The core ingredient of Striction D is super quality Natural Ceylon Cinnamon. Not just any Cinnamon will do – regular Cinnamon, the kind regularly used as a flavoring or found in the supermarket, is high in a compound called coumarin which can be toxic in high doses. Ceylon Cinnamon, known as “true Cinnamon”, is safe in quantity and is the only type of Cinnamon proven to help improve insulin response and carbohydrate metabolism, naturally with no side effects. Cinnamon has a long history of treating various health disorders, including high blood sugar. The bark of the plant provides the medicinal ingredients, including the essential oil that contains the strong fragrance and flavor. Numerous research studies have shown that this herb is beneficial in managing blood sugar.



Each Striction D capsule contains the clinically proven amount of a patented, purified form of Chromium called Crominex3+. Essential for healthy glucose metabolism, chromium is pivotal in maintaining a proper, healthy glucose metabolism. By utilizing Crominex3+, Striction D is able to deliver the safest, most potent form of Chromium – which has been clinically shown to increase insulin sensitivity by 17%, giving a stronger insulin resp onse ultimately leading to lower blood glucose levels.



Banaba leaf, a plant native to Sri Lanka, has been used in holistic medicine for treating diabetes for centuries. In order to harness all of the power found in the plant, Striction D relies on GlucoHelp – a purified extract of banaba leaf that has been clinically proven to reduce blood glucose levels by up to 30%. It also provides antioxidants that help transfer glucose into the cell, normalizing blood sugar and insulin levels.



Zinc is an essential mineral required for proper insulin production and secretion. Numerous studies have shown that patients with diabetes have lower levels of zinc in their blood, and zinc supplementation helps to improve their HbA1c. Studies have also shown that zinc supplementation in non-diabetics improved blood sugar control, demonstrating this mineral’s importance in blood sugar regulation. Striction D contains 100% of the body’s daily required intake of zinc, adding to its high potency.



Like Zinc, Thiamine is an essential mineral required for a healthy metabolism of fats, proteins, and most importantly – carbohydrates. Studies have shown that diabetics, and those suffering from metabolic syndromes, are often deficient in this important mineral. Clinically shown to promote a healthy metabolism, Thiamine can lead to lower blood glucose levels and more energy. Striction D contains 100% of the body’s daily required intake of thiamine, delivering the optimal amount to overcome any deficiency and get the most out of this powerhouse mineral!

60 Capsules per Bottle | 30 Day Supply | Other Ingredients: Hyromellose, Rice Flour, Magnesium Stearate (Vegetable), Silicon Dioxide



  1. Effects of a Water-Soluble Cinnamon Extract on Body Composition and Features of the Metabolic Syndrome in Pre-Diabetic Men and Women...
    HR and BP After 12-weeks, subjects in the Cinnulin group decreased their SBP by 3.8% (from 133 ± 14 mm Hg [pre] to 128 ± 18 mm Hg [post], P < 0.001) compared to subjects in the Placebo group (from 133 ± 22 mm Hg [pre] to 142 ± 20 mm Hg [post]). No between or within-group changes in diastolic blood pressure (Cinnulin: from 83 ± 6 mm Hg [pre] to 84 ± 9 mm Hg [post]; Placebo: from 83 ± 14 mm Hg [pre] to 86 ± 12 mm Hg [post], P < 0.32) or HR (Cinnulin: from 69 ± 14 beats/min [pre] to 69 ± 12 beats/min [post]; Placebo: from 71 ± 15 beats/min [pre] to 74 ± 8 beats/min [post], P < 0.73) were noted in either group.

    It also appears that this particular water-soluble cinnamon extract, standardized for polyphenolic type-A polymers, can favorably alter systolic blood pressure and body composition when consumed for at least 12-weeks.
  2. Cinnamon Extract Lowers Glucose, Insulin and Cholesterol in People with Elevated Serum Glucose
    Cinnamon has in vitro insulin potentiating activity, and proanthocyanidins from cinnamon prevent in vitro formation of advanced glycation end products…After 2 mo, fasting glucose decreased (p<0.001) in the cinnamon extract-supplemented group (8.85+/- 0.36 to 8.19+/- 0.29 mmol/L) compared with the placebo group (8.57+/- 0.32 to 8.44+/- 0.34 mmol/L, p=0.45). Glucose 2H after a 75 g carbohydrate load, fasting insulin, and HOMA-IR also decreased with cinnamon extract compared with placebo. Total and LDL-cholesterol decreased with cinnamon extract and HDL-cholesterol decreased in both the cinnamon-extract and placebo groups. In conclusion, supplementation with 500 mg of water-extract of cinnamon for two months reduced fasting insulin, glucose, total cholesterol, and LDL cholesterol and enhanced insulin sensitivity of subjects with elevated blood glucose.
  3. Efficacy and Safety of “True” Cinnamon as a Pharmaceutical Agent in Diabetes: A Systematic Review and Meta-Analysis
    The literature search identified 16 studies on C. zeylanicum (five in-vitro, six in-vivo and five in-vivo/in-vitro). However, there were no human studies. In-vitro C. zeylanicum demonstrated a potential for reducing post-prandial intestinal glucose absorption by inhibiting pancreatic α-amylase and α-glucosidase, stimulating cellular glucose uptake by membrane translocation of glucose transporter-4, stimulating glucose metabolism and glycogen synthesis, inhibiting gluconeogenesis and stimulating insulin release and potentiating insulin receptor activity. The beneficial effects of C. zeylanicum in animals include attenuation of diabetes associated weight loss, reduction of fasting blood glucose, LDL and HbA(1c), increasing HDL cholesterol and increasing circulating insulin levels. Cinnamomum zeylanicum neuropathy and nephropathy, with no significant toxic effects on liver and kidney and a significantly high therapeutic window.
  4. Cinnamon Use in Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis
    In a meta-analysis of 10 RCTs (n=543 patients), cinnamon doses of 120 mg/d to 6 g/d for 4 to 18 weeks reduced levels of fasting plasma glucose (-24.59 mg/dL ; 95% CI, -40.52 to -8.67 mg/dL), total cholesterol (-15.60 mg/dL ; 95% CI, -29.76 to -1.44 mg/dL), LDL-C (-9.42 mg/dL ; 95% CI, -17.21 to -1.63 mg/dL), and triglycerides (-29.59 mg/dL; 95% CI, -48.27 to -10.91 mg/dL). Cinnamon also increased levels of HDL-C (1.66 mg/dL; 95% CI, 1.09 to 2.24 mg/dL). No significant effect on hemoglobin A1c levels (-0.16%, 95% CI -0.39% to 0.02%) was seen. High degrees of heterogeneity were present for all analyses except HDL-C (1(2) ranging from 66.5% to 94.72%). The consumption of cinnamon is associated with a statistically significant decrease in levels of fasting plasma glucose, total cholesterol, LDL-C, and triglyceride levels, and an increase in HDL-C levels; however, no significant effect on hemoglobin A1c was found. The high degree of heterogeneity may limit the ability to apply these results to patient care, because the preferred dose of duration of therapy are unclear.
  5. Cinnamon Intake Lowers Fasting Blood Glucose: Meta-Analysis
    A meta-analysis of clinical studies of the effect of cinnamon intake on people with type 2 diabetes and/or prediabetes that included three new clinical trials along with five trials used in previous meta-analyses was done to assess cinnamon’s effectiveness in lowering fasting blood glucose. The eight clinical studies were identified using a literature search (Pub Med and Biosis through May 2010) of randomized, placebo controlled trials reporting data on cinnamon and/or cinnamon extract and FBG. Comprehensive meta-analysis (Biostat Inc., Englewood, NJ, USA) was performed on the identified data for both cinnamon and cinnamon extract intake using a random-effects model that determined the standardized mean difference (ie, Change 1 (control) – Change 2 (cinnamon) divided by the pooled SD of post scores). Cinnamon intake, either as whole cinnamon or as cinnamon extract, results in a statistically significant lowering in FBG (-0.49+/- 0.2 mmol/L; n=8, P=0.025) and intake of cinnamon extract only also lowered FBG (-0.48 mmol/L+/- 0.17; n=5, P=0.008). Thus cinnamon extract and/or cinnamon improves FBG in people with type 2 diabetes or prediabetes.
  6. Effects of Adjunct Therapy of a Proprietary Herbo-Chromium Supplement in Type 2 Diabetes: A Randomized Clinical Trial
    “…Better control of fasting blood glucose and post-prandial blood glucose levels were observed in patients receiving HCrS (-12.4 to -16.6%) compared to placebo groups (-3.4 to -9.4%). There was a 5.5-7.4% decrease in HsCRP and LDL levels in patients receiving HCrS, which is better than placebo treated groups. Significant decrease in urinigy microalbumin level was observed in patients receiving HCrS (-20.0 to -22.5%) compared to placebo groups (-7.8 to -11.6%). Significant decreases in diabetic symptoms were observed in patients receiving HCrS (-47.4 to -59.4%) compared to that observed in placebo groups (-18.0 to 34.0%). Conclusion: The findings indicate that HCrS with OAD improves overall diabetic complications within 2 months and may be useful in long-term therapy.”
  7. Effect of Proprietary Chromium Complex and its Individual Components Versus Chromium Picolinate, Chromium Polynicotinate and Chromium Dinicocysteinate on Endothelial Function, Biomarkers and Lipid Profile in Type 2 Diabetics – A Randomized, Double-Blind, Placebo-Controlled Study
    “…PPC 400mcg showed significant improvement in endothelial function, lipid profile and biomarkers of oxidative stress in type 2 diabetics, followed by the combination of Phyllanthus emblica and Shilajit extract, chromium picolinate, chromium polynicotinate, chromium dinicocysteinate and chromium chloride. Further, it can be inferred that PPC 400 mcg has significant synergistic activity.”
  8. Anti-Arthritic Efficacy And Safety Of Crominex® 3+ (Trivalent Chromium, Phyllanthus emblica Extract, And Shilajit) In Moderately Arthritic Dogs
    “…Findings of this investigation revealed that dogs receiving Crominex 3+ (1000 µg chromium, 15 mg Amla extract and 15 mg purified Shilajit per day in two divided doses) exhibited a significant (P<0.05) reduction in arthritic pain noted as early as after 90 days with a maximum reduction after 150 days of treatment. Pain level remained the same or slightly increased in the dogs receiving placebo. No significant change occurred in physical parameters or serum biomarkers in dogs on placebo or Crominex 3+, which suggested that Crominex 3+ was well tolerated by arthritic dogs. In conclusion, Crominex 3+ significantly (P<0.05) ameliorated arthritic pain and improved quality of life without causing any untoward effects in moderately arthritic dogs.”
  9. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciose L.) and Corosolic Acid
    Banaba (Lagerstroemia speciosa L.) extracts have been used for many years in folk medicine to treat diabetes, with the first published research study being reported in 1940. This paper summarizes the current literature regarding Banaba and its constituents. The hypoglycemic effects of Banaba have been attributed to both corosolic acid as well as ellagitannins. Studies have been conducted in various animal models, human subjects, and in vitro systems using water soluble Banaba leaf extracts, corosolic acid, and ellagitannins. Corosolic acid has been reported to decrease blood sugar levels within 60 min in human subjects. Corosolic acid also exhibits antihyperlipidemic and antioxidant activities. The beneficial effects of Banaba and corosolic acid with respect to various aspects of glucose and lipid metabolism appear to involve multiple mechanisms, including enhanced cellular uptake of glucose, impaired hydrolysis of sucrose and starches, decreased gluconeogenesis, and the regulation of lipid metabolism. These effects may be mediated by PPAR and other signal transduction factors. Banaba extract, corosolic acid, and other constituents may be beneficial in addressing the symptoms associated with metabolic syndrome, as well as offering other health benefits.
  10. Antidiabetic Activity of a Standardized Extract (Glucosol) from Lagerstroemia speciose Leaves in Type 2 Diabetics. A Dose-Dependence Study
    The antidiabetic activity of an extract from the leaves of Lagerstroemia speciosa standardized to 1% corosolic acid (Glucosol) has been demonstrated in a randomized clinical trial involving Type II diabetics (non-insulin-dependent diabetes mellitus, NIDDM). Subjects received a daily oral dose of Glucosol and blood glucose levels were measured. Glucosol at daily dosages of 32 and 48mg for 2 weeks showed a significant reduction in the blood glucose levels. Glucosol in a soft gel capsule formulation showed a 30% decrease in blood glucose levels compared to a 20% drop seen with dry-powder filled hard gelatin capsule formulation (P<0.001), suggesting that the soft gel formulation has a better bioavailability than a dry-powder formulation.
  11. Corosolic Acid Induces GLUT4 Translocation in Genetically Type 2 Diabetic Mice
    The effect of corosolic acid (CA) on blood glucose was studied in KK-Ay mice, an animal model of type 2 diabetes. CA (10 mg/kg) reduced the blood glucose (p<0.05) of KK-Ay mice 4 h after single oral administration when compared with the control group. However, CA did not change the plasma insulin. The muscle facilitative glucose transporter isoform 4 (GLUT4) translocation from low-density microsomal membrane to plasma membrane was significantly increased in the orally CA-treated mice when compared with that of the controls (p<0.05). These results suggest that the hypoglycemic effect of CA is derived, at least in part, from an increase in GLUT4 translocation in muscle. Therefore, it may be that CA has beneficial effects on hyperglycemia in type 2 diabetes.
  12. Activation of Insulin Receptors by Lagerstroemin
    Lagerstroemin, an ellagitannin isolated from the leaves of Lagerstroemia speciosa (L.) Pers. (Lythraceae), was examined for its biological activities. In rat adipocytes, the compound increased the rate of glucose uptake and decreased the isoproterenol-induced glycerol release. In Chinese hamster ovary cells expressing human insulin receptors, it increased the Erk activity. These insulin-like actions were accompanied by the increased tyrosine-phosphorylation of the beta-subunit of the insulin receptors. Tryptic digestion of the extracellular sites of the insulin receptors markedly increased the effective concentrations of insulin without changing those of lagerstroemin. Thus lagerstroemin was considered to cause its insulin-like actions by a mechanism different from that employed by insulin.
  13. Ellagitannins from Lagerstroemia speciose as Activators of Glucose Transport in Fat Cells
    Glucose transport enhancers were searched for in Lagerstroemia speciosa, a Philippine local herbal medicine used for diabetes mellitus. Bioassay-guided fractionation of the aqueous acetone extract of the leaves afforded three active ellagitannins, lagerstroemin, flosin B and reginin A, identified by NMR and optical rotation. These compounds increased glucose uptake of rat adipocytes, and could be responsible for lowering the blood glucose level.
  14. Thiamine Deficiency in Diabetes Mellitus and the Impact of Thiamine Replacement on Glucose Metabolism and Vascular Disease
    Despite the targeting of traditional risk factors for cardiovascular disease, disease burden has not been completely eliminated. Thiamine is an essential cofactor in carbohydrate metabolism and individuals with diabetes are thiamine deficient. The pathophysiology of recognised complications of thiamine deficiency is similar to that underlying atherosclerosis and the metabolic syndrome, namely oxidative stress, inflammation and endothelial dysfunction. This review examines the mechanisms by which thiamine deficiency occurs in individuals with diabetes, how this deficiency leads to hyperglycaemic-induced damage, and the effect of thiamine replacement on vascular disease, endothelial function and oxidative stress. Thiamine administration can prevent the formation of harmful by-products of glucose metabolism, reduce oxidative stress and improve endothelial function. The potential benefit of long-term replacement in those with diabetes is not yet known but may reduce cardiovascular risk and angiopathic complications.
  15. The impact of Thiamine Treatment in the Diabetes Mellitus
    Thiamine acts as a coenzyme for transketolase (Tk) and for the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes, enzymes which play a fundamental role for intracellular glucose metabolism. The relationship between thiamine and diabetes mellitus (DM) has been reported in the literature. Thiamine levels and thiamine-dependent enzyme activities have been reduced in DM. Genetic studies provide opportunity to link the relationship between thiamine and DM (such as Tk, SLC19A2 gene, transcription factor Sp1, α-1-antitrypsin, and p53). Thiamine and its derivatives have been demonstrated to prevent the activation of the biochemical pathways (increased flux through the polyol pathway, formation of advanced glycation end-products, activation of protein kinase C, and increased flux through the hexosamine biosynthesis pathway) induced by hyperglycemia in DM.Thiamine definitively has a role in the diabetic endothelial vascular diseases (micro and macroangiopathy), lipid profile, retinopathy, nephropathy, cardiopathy, and neuropathy.
  16. Zinc as a Potential Coadjuvant in Therapy for Type 2 Diabetes
    Cellular and animal models provide information on the insulin mimetic action of zinc, as well as its role as a regulator of oxidative stress, inflammation, apoptosis, and insulin secretion. Zinc supplementation studies in humans are limited, although some positive effects have been reported; mainly, a modest but significant reduction in fasting glucose and a trend to decreased glycated hemoglobin (HbA1c). Zinc supplementation may have beneficial effects on glycemic control. Nevertheless, among the studies considered, the vast majority lasted for 6 months or less, suggesting the importance of conducting long-duration studies given the characteristics of type 2 diabetes as a chronic disease.
  17. Is Dietary Zinc Protective for Type 2 Diabetes? Results from the Australian Longitudinal Study on Women’s Health
    From 8921 participants, 333 incident cases of type 2 diabetes were identified over 6 years of follow-up. After adjustment for dietary and non-dietary factors, the highest quintile dietary zinc intake had almost half the odds of developing type 2 diabetes (OR = 0.50, 95% C.I. 0.32–0.77) compared with the lowest quintile. Similar findings were observed for the zinc/iron ratio; the highest quintile had half the odds of developing type 2 diabetes (OR = 0.50, 95% C.I 0.30-0.83) after multivariable adjustment of covariates. Higher total dietary zinc intake and high zinc/iron ratio are associated with lower risk of type 2 diabetes in women. This finding is a positive step towards further research to determine if zinc supplementation may reduce the risk of developing type 2 diabetes.
  18. Is Serum Zinc Level associated with Prediabetes and Diabetes? A Cross-Sectional Study from Bangladesh
    A total of 280 participants were analysed. On fasting blood sugar results, 51% were normal, 13% had prediabetes and 36% had diabetes. Mean serum zinc level was lowest in prediabetic compared to normal and diabetic participants (mean differences were approximately 65 ppb/L and 33 ppb/L, respectively). In multiple linear regression, serum zinc level was found to be significantly lower in prediabetes than in those with normoglycemia. Beta cell function was significantly lower in prediabetes than normal participants. Adjusted linear regression for HOMA parameters did not show a statistically significant association between serum zinc level, beta cell function (P = 0.07) and insulin resistance (P = 0.08). Low serum zinc accentuated the increase in insulin resistance seen with increasing BMI. Participants with prediabetes have lower zinc levels than controls and zinc is significantly associated with beta cell function and insulin resistance. Further longitudinal population based studies are warranted and controlled trials would be valuable for establishing whether zinc supplementation in prediabetes could be a useful strategy in preventing progression to Type 2 diabetes.

  19. Chromium and Polyphenols from Cinnamon Improve Insulin Sensitivity
    Naturally-occurring compounds that have been shown to improve insulin sensitivity include Cr and polyphenols found in cinnamon (Cinnamomon cassia). These compounds also have similar effects on insulin signalling and glucose control. The signs of Cr deficiency are similar to those for the metabolic syndrome and supplemental Cr has been shown to improve all these signs in human subjects. In a double-blind placebo-controlled study it has been demonstrated that glucose, insulin, cholesterol and HbA1c are all improved in patients with type 2 diabetes following Cr supplementation. It has also been shown that cinnamon polyphenols improve insulin sensitivity in in vitro, animal and human studies. Cinnamon reduces mean fasting serum glucose (18-29%), TAG (23-30%), total cholesterol (12-26%) and LDL-cholesterol (7-27%) in subjects with type 2 diabetes after 40 d of daily consumption of 1-6 g cinnamon. Subjects with the metabolic syndrome who consume an aqueous extract of cinnamon have been shown to have improved fasting blood glucose, systolic blood pressure, percentage body fat and increased lean body mass compared with the placebo group. Studies utilizing an aqueous extract of cinnamon, high in type A polyphenols, have also demonstrated improvements in fasting glucose, glucose tolerance and insulin sensitivity in women with insulin resistance associated with the polycystic ovary syndrome. For both supplemental Cr and cinnamon not all studies have reported beneficial effects and the responses are related to the duration of the study, form of Cr or cinnamon used and the extent of obesity and glucose intolerance of the subjects.
  20. Cinnamon Extracts Boost Insulin Sensitivity